Side-by-side comparison of AI visibility scores, market position, and capabilities
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
2024 Revenue: KRW 175.2T (+7.7% YoY) | Operating Profit: KRW 14.2T (-5.9%) | Vehicle Sales: 4.14M units (-1.8%) | Q4 2024: Revenue KRW 46.62T (+11.9%), Op Profit KRW 2.82T (-17.2%) | Electrified Vehicles: 757k units (+8.9%, 21.8% of sales) | US Market: 988k units (+9%) | 2025 guidance: 3-4% revenue growth, 7-8% op margin
Hyundai Motor Company was founded in 1967 in Seoul, South Korea, by Chung Ju-yung and has grown into one of the world's largest automotive manufacturers, ranking third globally by vehicle sales. From its origins as a budget-focused automaker producing affordable, practical vehicles for emerging markets, Hyundai has transformed over the past two decades into a technology-forward brand competing directly with European and Japanese premium manufacturers. Its mission centers on delivering smart mobility solutions for a sustainable future.\n\nHyundai's product lineup spans mass-market sedans, SUVs, and commercial vehicles, alongside its premium Genesis brand and the Ioniq dedicated EV lineup. The Ioniq 5, Ioniq 6, and Ioniq 7 have emerged as critically acclaimed electric vehicles, with the Ioniq 5 winning the World Car of the Year award. Hyundai is also investing heavily in hydrogen fuel cell technology, autonomous driving, and robotics through subsidiaries including Boston Dynamics. Its vehicles are sold in over 200 countries through a network of more than 6,000 dealerships.\n\nHyundai reported revenue of KRW 175.2 trillion in 2024, a 7.7% year-over-year increase, with Q4 2024 revenue of KRW 46.62T (+11.9%). The company sold 4.14M vehicles globally in 2024. With major EV manufacturing investments underway in the United States (Metaplant America in Georgia), Hyundai is positioning itself to be a top-three EV manufacturer globally by 2030, backed by robust R&D spending and a vertically integrated battery and platform strategy.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.